The Cancer Research Consortium of West Michigan (CRCWM), formed by two experienced Clinical Community Oncology Programs (CCOPs), a NCI Community Cancer Centers Program, one medical school and a basic science institute is ideally positioned to fulfill the role of a NCORP. CRCWM has a committed group of eleven health systems, 90+ knowledgeable investigators and a well-established administrative structure. CRCWM is a large accrue to NCI clinical trials and is able to enroll minorities, underserved and rural individuals. As demonstrated in this application, CRCWM is experienced in Cancer Care Delivery Research (CCDR) and committed to further development of resources to make additional contributions to this NCI initiative.
The specific aims of the CRCWM are: 1. To maximize the accrual of patients to cancer clinical trials sponsored by the National Cancer Institute. 2. To become strong contributors to Cancer Care Delivery Research (CCDR). 3. To address health care disparities by expanding accrual of underserved and minority populations through enhanced relationships with community partners. 4. To maximize the adoption of NCI scientific findings into clinical care through education and engagement of clinical partners and health systems. 5. To expand our network and health system partnerships (rural and urban, large and small) in order to bring NCI clinical trials and education to targeted populations. 6. T develop and mentor young investigators and expand our leadership roles in the emerging National Clinical Trials Network (NCTN) in order to optimize our contribution to the national scientific agenda.
Eleven health systems have joined together to conduct research and to be a large accrue to NCI clinical trials. Our combined programs cover the west half of Michigan to care for almost 9,000 newly diagnosed cancer patients and their families per year. CRCWM is ideally positioned both structurally and in patient diversity to contribute to the NCI NCORP research initiatives.
|Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527|
|Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952|
|Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2017) A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806. Am J Hematol :|
|Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18|
|Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91|
|Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74|
|Stephens, Deborah M; Li, Hongli; LeBlanc, Michael L et al. (2016) Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004|
|Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7|